Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma
Sydney, Australia 23 August 2022 Highlights Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2 Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as…